QT Ultrasound is a privately held technology company engaged in the research, development and commercialization of an innovative automated breast imaging system producing high-resolution transmission ultrasound images.
Approximately 39 million women, in the United States, get mammograms every year (source: CDC). For every 1 woman with cancer, 19 more will be told they might have cancer when they don’t. The cost, time, and psychological distress takes an enormous toll. We exist to change the paradigm of breast imaging and to keep women from going through the trauma of this journey. It’s why the FDA granted clearance for the QTscan as an adjunct to mammography, and the National Institutes of Health (NIH) awarded $16 million in funding to continue QT Ultrasound research.
QT Ultrasound is founded and led by a medical doctor and managed by some of the best talent in their fields.
Dr. Klock has served as Chief Executive Officer of the Company since 2014 and as Managing Director, Manager and Founder of the Company since 2011. Prior to QT Ultrasound, Dr. Klock was involved in the start-up of five medical companies, including Co-Founder and President of BioMarin Pharmaceutical, which successfully commercialized five FDA approved drugs; Scientific Founder and Vice President of Research of Glycomed, now Ligand Pharmaceutical; and founding investor in Ultragenyx Pharmaceutical. He also personally brought to market a novel cancer treatment, the first rapid AIDS test, comprehensive tests for detecting metabolic diseases in children, and several drugs for treating pediatric genetic conditions. Dr. Klock has authored over 70 peer-reviewed medical and scientific publications, and eight granted patents.
Dr. Lenox is an electrical and computer engineer with many years of research and development and product development experience in medical imaging. Prior to joining the Company, he was director of medical imaging at the Texas Institute for Preclinical Studies and a Professor of Biomedical Engineering at Texas A & M University. Prior to his academic work, he was director of New Product Development at CTI-PET Systems, manufacturer of the first commercial PET and PET-CT scanners. Dr. Lenox is author of over 70 publications and ten patents.
Dr. Natesan is a board-certified radiologist who brings together years of experience in finance and healthcare. Prior to joining QT Ultrasound, Dr. Natesan led multiple mergers, acquisitions, and financing deals in the medical device, biotech, and pharmaceutical industries, as an investment banker in Lehman Brothers’ Healthcare Group. Dr. Natesan has also served as an Assistant Professor of Diagnostic Radiology at the UT-MD Anderson Cancer Center, and has contributed to multiple publications, national presentations, and grant-funded research in imaging economics.
Mr. LoVetri has experience in manufacturing, software, and IT with industry leaders such as GE, Autodesk, Charles Schwab and BioRad Laboratories. He has an MS in Engineering and proven leadership in enterprise management and bringing products to market.
Margaret Donigan brings strategy, investing, and operating experience to the company with particular focus on driving shareholder value. Prior to joining QT Ultrasound, she spent over a decade in middle market private equity, leading strategy development and making principal investments in more than a dozen companies, covering a variety of industries including healthcare. Ms. Donigan served as Executive Vice President of Corporate Development at Paradigm Tax Group, a company for which she led the recapitalization and served on the Board. She received her B.A. from Yale University and earned her M.B.A. in Finance and Operations Management from the Wharton School at the University of Pennsylvania, where she graduated as a Palmer Scholar. Ms. Donigan also serves as the Chief Strategy Officer QTbreasthealth™, a wholly owned subsidiary.
For over three decades Mr. Pirshafiey has developed products and businesses for domestic and multinational firms. Mr. Pirshafiey’s creativity, innovative problem-solving skills, and entrepreneurial mindset have provided professional, technical, and business solutions to many start-ups and mature companies. He has previously founded and managed two companies with the mission to provide sustainable practices to industries such as medical devices, automotive, aerospace, high-tech, consumer products, and robotics (brief client list: Johnson & Johnson, Siemens, Edwards Life Sciences, Autoliv, TRW). Mr. Pirshafiey has 16 inventions filed with the US patent office, holds a Bachelor of Science in Aeronautical Engineering, and an MBA with specialization in Entrepreneurship.
Ms. Rudy is a graduate from UCLA with a B.S. in Mathematics and a Specialization in Computing. She worked for 2 ½ year at Ernst & Young in the audit practice in San Francisco where she obtained her CPA license. She then had the amazing opportunity to work for 21 years at Lucasfilm Ltd. in the Corporate Accounting group where she was the Assistant Controller. While there she was responsible for all the day-to-day accounting as well as annual audits, consolidation of 20+ legal entities, foreign production audits, system implementations and inventory of Star Wars costumes.
Brian Brothen brings to QT Ultrasound more than two decades of commercial pharmaceutical, diagnostic, and medical device oncology experience including sales, commercial leadership, business development, strategic planning, and key opinion leader development. Prior to joining QT Ultrasound, Mr. Brothen was the Vice President of Sales at Paradigm Dx. During his time at Paradigm Dx, he led the launch of the company’s new NGS cancer diagnostic test to help deliver personalized cancer therapy. Mr. Brothen has held numerous oncology sales and sales leadership positions at Agendia, Pharmion (Celgene), Sanofi, and Schering Plough. Mr. Brothen graduated from the University of South Florida with a degree in Business and Communications.
The company is managed by a Board of Managers. Each member has achieved the highest level of success in their field and offers a unique skill set and a valuable strategic contribution.
John C. Klock, M.D. has served as Chief Executive Officer of the Company since 2014 and as Managing Director, Manager and Founder of the Company since 2011.
Prior to QT Ultrasound, Dr. Klock was involved in the start-up of five medical companies, including Co-Founder and President of BioMarin Pharmaceutical, which successfully commercialized five FDA approved drugs; Scientific Founder and Vice President of Research of Glycomed, now Ligand Pharmaceutical; and founding investor in Ultragenyx Pharmaceutical. He also personally brought to market a novel cancer treatment, the first rapid AIDS test, comprehensive tests for detecting metabolic diseases in children, and several drugs for treating pediatric genetic conditions.
Dr. Klock has authored over 70 peer-reviewed medical and scientific publications, and 8 granted patents.
Kenneth G. Hungerford ii has served as Lead Manager of the Company since 2014 and Founder of the Company since 2011. Mr. Hungerford also served as the Company’s Chairman of the Board of Managers from 2011 to 2014. Mr. Hungerford had been a member of the Board of Directors of TechniScan from 2007 to 2011, and served as Chairman of the Board of TechniScan from 2009 until 2011.
Mr. Hungerford is currently Lead Director of ADAC Automotive, Inc., a privately held automotive supplier, and has previously served as its Chairman from January 1986 to December 2015. Mr. Hungerford was a founding director of Edge Industries, a privately held capital equipment manufacturer that provides specialized cutting, metering, and dispensing systems for the urethane industry; Lomak Petroleum, which was merged into Range Resources, a publicly traded oil and gas company engaged in the acquisition and development of gas resources; Applied Image Technology, a development stage software company that provides computer based parts manuals, which was merged into MRO, Inc., a publicly traded software company, that was subsequently acquired by IBM; Brilliance Audiobooks, a publisher of audio books, which was recently acquired by Amazon; and WXMI Broadcasting, an independent, local television station in Grand Rapids, Michigan that became the local FOX network affiliate, and was subsequently sold to COX Broadcasting.
Additionally, Mr. Hungerford served on the Board of Trustees of St. Mary’s Health Care in Grand Rapids, Michigan, which is a member organization in the Trinity Health Network. Mr. Hungerford received a Bachelor of Business Administration degree from the University of Notre Dame in 1968 and has been registered as a Certified Public Accountant in the State of Michigan since 1970.
Carl Jandernoa has served as a Manager of the Company since 2012. Mr. Jandernoa is an officer and an owner of 42 North Partners, LLC, a privately held investment company located in Grand Rapids, Michigan which specializes in venture capital and growth capital investments. He previously served as a Vice President of Bridge Street Capital Partners, LLC, a growth capital private equity firm located in Grand Rapids, Michigan. Mr. Jandernoa also worked in the Global IT Product Management Department at UBS Financial Services, Inc. and was an auditor at Deliotte & Touche. Mr. Jandernoa graduated with a Bachelor of Science degree in Accounting from Marquette University.
Robert Y. Kessler has served as a Manager of the Company since 2012. He is a Manager and an owner of Biotex Pharma Investments, LLC, a privately-held investment fund located in New York City, New York, which specializes in pharmaceuticals and medical devices.
John J. Meilner has served as a Manager of the company since 2018. He is the President of 42 North Partners, LLC serving a single multi-generational family office. John is responsible for overall managerial leadership of the business as well as directing the investment team with a primary focus of investing in operating companies either directly or in partnership with other investors. Additionally, John is a Founder and Managing Partner of Bridge Street Capital Partners, an investment management firm providing growth capital to companies across a variety of industries.
Previously, John served seven years as Managing Director in the Investment Banking group of McDonald Investments, Inc. (acquired by KeyCorp). Prior to joining McDonald, John spent thirteen years at Deloitte & Touche LLP, serving the last two years as Partner.
John is a CPA and has a Bachelor of Science degree in Accounting from Drake University and a Masters of Management degree from Northwestern University’s Kellogg Graduate School of Management.
In addition to Board of Director roles associated with 42 North Partners and Bridge Street Capital, John serves as an independent director on the board of directors for a fifth-generation family business holding company and previously for a bank holding company located in the Midwest. Finally, John has been actively engaged throughout his career on many community boards and presently works in a mentoring capacity for young entrepreneurs.